Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    In-person & Online

    Hospitalization Experiences of South Asian and Arab Older Adults with Dementia and Their Caregivers

    What is this Study about?

    This study aims to explore the hospitalization experiences of South Asian and Arab older adults with dementia and identify barriers and facilitators they encounter during their hospital stay in receiving culturally safe care. The information gathered will be used to identify gaps in current hospital dementia care practices and create resources and recommendations for policy and practice changes that promote culturally safe, inclusive dementia care for ethnic communities.

    Eligibility Criteria

    You are eligible to participate if you are:

    Older Adults:

    • an older adult aged 60 years or older
    • from the South Asian or Arab community
    • living in Edmonton
    • living with a diagnosis of dementia or currently undergoing the diagnostic process
    • currently hospitalized or have experienced hospitalization within the past year

    Caregivers

    • from the South Asian or Arab community
    • involved in caring for a family member living with dementia during hospitalization and hospital stay

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)

    What is this Study about?

    The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

    Eligibility Criteria

    Male or female participants aged 50 years of age
    Has a history of previous clinical intracerebral hemorrhage.
    Has probable CAA.

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Toward Digital Phenotyping of Healthy and Pathological Cognitive Aging

    What is this Study about?

    This study investigates whether digital activity data collected from wearable and mobile devices can be used to understand changes in cognitive functioning associated with aging and neurological conditions. Participants’ daily movement patterns and activity behaviors will be monitored using advanced tracking technology that collects detailed spatial and temporal data. Researchers will analyze these patterns using computational methods to identify digital markers associated with cognitive functioning. 

    Eligibility Criteria

    You are eligible to participate if you are 60 years or older, have a confirmed diagnosis of Alzheimer’s disease, remain relatively independent in your day-to-day life, are able and willing to wear digital activity tracking technology to monitor daily activity patterns, and are able to provide informed consent and participate in study procedures. You are also eligible to participate if you are a partner/caregiver as a healthy control. 

    Recruitment End Date

    Find Out More